February 10, 2008   Sign In |  About ebizQ |  Contact Us |  Join ebizQ Gold Club
Sandy Kemsley
Column 2
The archive of Sandy Kemsley's blog on business process management, enterprise architecture, business intelligence and technology in business.

« Milk, butter and business processes | Main | Modelling for the masses »

October 16, 2006
Enterprise Architecture in pharmaceuticals

It was Craig Confoy's presentation on Johnson & Johnson Pharma where I really started to get interested in the issue of where EA sits in the enterprise. Although the "E" in EA stands for "Enterprise", it seems that most organizations, and J&J is no exception, start out with EA in the IT infrastructure group somewhere. Like many large conglomerates, they had a bit of a mess with five pharmaceutical R&D companies (out of J&J's 200-odd companies), each with its own IT department supporting 14 different functional units per company, and little alignment between the company functions. Since EA was in IT infrastructure, anything in the business layers of EA, such as business modelling, was done on a project-by-project basis and not shared between business units or companies.

Sound familiar? Almost every large company that I deal with has the same issues: some real architecture going on at the lower infrastructure levels, but practically none at the business levels.

About 5 years ago, J&J Pharma decided to do something about it, and created a business architecture group. There were a few stumbles along the way, such as the use of a (seemingly inappropriate) CASE tool that resulted in business process documentation that stretched over 42 feet at 8pt font -- unusable and unsustainable -- before they started using Proforma.

One of their models that I really liked was an enterprise data model that could be overlaid with departmental ownership, so that you can easily see how changing any part of the model would impact which departments. I think that this is one of the basics required by any large organization, but often not used; instead, companies tend to replicate data on a per-department basis since they don't have any enterprise data models that would tell them who is using what data.

This was one customer presentation that showed some clear ROI of using the Proforma tools: they found that systems could be implemented 30% faster (a huge advantage in pharmaceuticals), that the modelling process identifies system integration points and allows them to create standard EAI models for reuse, and that the data models helped meet their regulatory requirements more easily.

Posted by Sandy Kemsley at 11:54 AM in BPA • EnterpriseArchitecture • ProformaVision2006 | Digg This | Add to del.icio.us

Trackback Pings

TrackBack URL for this entry:
http://www.ebizq.net/mt/mt-tb.cgi/813

Most Recent ebizQ Blog Entries
ADVERTISEMENT

The content of all blog posts are copyright © 2007, Sandy Kemsley. All rights reserved. You may not reproduce any of these posts in their entirety without the author's express permission, although "fair use" excerpts are permitted as long as they include a link back to the original post.

Disclaimer:The opinions expressed in this blog are solely representative of the blog's author, and not of ebizQ.
Subscribe to our Newsletters
ebizQ Weekly Gold Club Update
Live Webinar Updates
Updates from ebizQ Partners
ebizQ SOA Update
ebizQ BPM Update
ebizQ Security Update
ebizQ BI Update
ebizQ Open Source Software Update
Virtual Show Newsletter
Your E-mail Address:
BAM: The Killer App for CEP
Date: Feb 12, 2008
Time: 12:00 PM ET
(17:00 GMT)

I WANT TO ATTEND
Event Processing Market Pulse
Date: Feb 14, 2008
Time: 12:00 PM ET
(17:00 GMT)

I WANT TO ATTEND
Archived Webinars | Upcoming Webinars

Marketing Solutions | Feedback | About ebizQ | Unsubscribe | Privacy Policy | Site Map